Erel Joffe MD

Physician

530 East 74thMSKCC-KochNew York, NY 10021
Phone+1 646-608-3703
Fax+1 929-321-8156

Dr. Joffe is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Joffe's full profile Already have an account?

Summary

I am a lymphoma specialist, hemato-oncologist and biomedical informatician. I specialize in treating all types of lymphoma, and have a special research focus on follicular, small lymphocytic, marginal zone, and mantle cell lymphomas. I also have extensive experience in treating more aggressive types, such as Diffuse-Large B-cell, Hodgkin’s, and Burkitt’s lymphomas. I am grateful and honored to be part of MSK’s lymphoma team, delivering the most cutting-edge care to our patients.

Education & Training

Tel Aviv University SacklerClass of 2007

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
MI State Medical License 2026 - 2029
NY State Medical License 2018 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Clinical Trials

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2018 Oct 24
COMPLETED
PHASE1, PHASE2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) Start of enrollment: 2017 Dec 28
RECRUITING
PHASE1, PHASE2
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2019 Apr 03
COMPLETED
PHASE1

Publications & Presentations

PubMed

Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.
Magdalena Corona, Aaron Gillmor, Kimon V Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva
Blood Cancer Discovery. 2026-08-31
1 citations
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.
Erel Joffe, Manik Uppal, Serena Zheng, Kurt S Bantilan, Connie Batlevi
Haematologica. 2026-08-01
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in-Mutated Diffuse Large B-Cell Lymphoma.
Manik Uppal, Bhavneet Bhinder, Andrew R Marderstein, Connie Lee Batlevi, Lorenzo Falchi
Journal of Clinical Oncology. 2026-07-20

Abstracts/Posters

Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
Erel Joffe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019